Pfizer Gross Profit 2010-2024 | PFE

Pfizer annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Pfizer gross profit for the quarter ending March 31, 2024 was $11.500B, a 15.44% decline year-over-year.
  • Pfizer gross profit for the twelve months ending March 31, 2024 was $31.442B, a 50.8% decline year-over-year.
  • Pfizer annual gross profit for 2023 was $33.542B, a 49.17% decline from 2022.
  • Pfizer annual gross profit for 2022 was $65.986B, a 30.75% increase from 2021.
  • Pfizer annual gross profit for 2021 was $50.467B, a 52.16% increase from 2020.
Pfizer Annual Gross Profit
(Millions of US $)
2023 $33,542
2022 $65,986
2021 $50,467
2020 $33,167
2019 $32,851
2018 $31,838
2017 $41,318
2016 $40,502
2015 $39,203
2014 $40,028
2013 $41,998
2012 $44,836
2011 $48,535
2010 $50,377
2009 $40,810
Pfizer Quarterly Gross Profit
(Millions of US $)
2024-03-31 $11,500
2023-12-31 $6,482
2023-09-30 $3,963
2023-06-30 $9,497
2023-03-31 $13,600
2022-12-31 $14,640
2022-09-30 $16,575
2022-06-30 $19,094
2022-03-31 $15,677
2021-12-31 $14,102
2021-09-30 $14,103
2021-06-30 $11,903
2021-03-31 $10,359
2020-12-31 $8,716
2020-09-30 $8,270
2020-06-30 $8,038
2020-03-31 $8,143
2019-12-31 $1,400
2019-09-30 $10,078
2019-06-30 $10,688
2019-03-31 $10,685
2018-12-31 $341
2018-09-30 $10,604
2018-06-30 $10,550
2018-03-31 $10,343
2017-12-31 $10,447
2017-09-30 $10,324
2017-06-30 $10,236
2017-03-31 $10,311
2016-12-31 $10,415
2016-09-30 $9,960
2016-06-30 $9,973
2016-03-31 $10,154
2015-12-31 $10,636
2015-09-30 $9,868
2015-06-30 $9,673
2015-03-31 $9,026
2014-12-31 $10,416
2014-09-30 $9,993
2014-06-30 $10,311
2014-03-31 $9,308
2013-12-31 $10,764
2013-09-30 $10,356
2013-06-30 $10,731
2013-03-31 $10,147
2012-12-31 $10,460
2012-09-30 $10,644
2012-06-30 $11,592
2012-03-31 $12,140
2011-12-31 $9,612
2011-09-30 $13,200
2011-06-30 $12,914
2011-03-31 $12,809
2010-12-31 $12,350
2010-09-30 $12,205
2010-06-30 $13,448
2010-03-31 $12,374
2009-12-31 $12,291
2009-09-30 $9,832
2009-06-30 $9,228
2009-03-31 $9,459
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $161.838B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.337B 110.33
Novo Nordisk (NVO) Denmark $606.535B 46.61
Johnson & Johnson (JNJ) United States $363.986B 14.46
Merck (MRK) United States $331.190B 60.26
AbbVie (ABBV) United States $287.713B 14.87
AstraZeneca (AZN) United Kingdom $245.493B 21.34
Novartis AG (NVS) Switzerland $210.205B 14.90
Sanofi (SNY) $123.824B 11.68
Innoviva (INVA) United States $1.008B 7.08